SCHEMBL2292202

SCHEMBL2292202

O=C(Nc1cccc(F)c1)ON=C1CCN(S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
TSHR P16473 1/20 0.49
MAPT P10636 3/20 0.49
HTT P42858 3/20 0.49
XBP1 P17861 1/20 0.49
LMNA P02545 3/20 0.48
ALDH1A1 P00352 3/20 0.48
HSD17B10 Q99714 2/20 0.48
CASP1 P29466 1/20 0.48
EPHX2 P34913 2/20 0.47
TP53 P04637 1/20 0.46
MAPK1 P28482 1/20 0.46
CYP2C9 P11712 3/20 0.45
USP2 O75604 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HIF1A Q16665 1/20 0.45
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292379 0.92 TSHR (0.50) MEN1KMT2ATSHRMAPTHTT
SCHEMBL2291074 0.92 LMNA (0.53) MEN1KMT2AMAPTHTTLMNA
SCHEMBL2289836 0.87 EPHX2 (0.47) MEN1KMT2AMAPTHTTLMNA
SCHEMBL2294071 0.87 ALDH1A1 (0.51) MEN1KMT2AMAPTHTTLMNA
SCHEMBL2295386 0.86 KMT2A (0.51) MEN1KMT2ATSHRMAPTLMNA
SCHEMBL2295416 0.86 KMT2A (0.54) MEN1KMT2ATSHRMAPTHTT
SCHEMBL2296034 0.85 KMT2A (0.51) MEN1KMT2ATSHRMAPTLMNA
SCHEMBL2292594 0.85 ALDH1A1 (0.52) HTTLMNAALDH1A1HSD17B10CYP2C9
SCHEMBL2296051 0.85 PKM (0.52) MEN1KMT2AMAPTHTTLMNA
SCHEMBL2294491 0.85 EPHX2 (0.45) MEN1KMT2AMAPTHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF CACNA1E, CACNA1B, CACNA1S MEN1 3484/4885KMT2A 2564/4885TSHR 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.